FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 2 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package MOST POPULAR Getting Help for Sexual Health Problems When You Have Head and... April 14, 2022 Bringing a Piece of Home to the Hospital April 4, 2023 Seven Centres to form new Cancer Research UK network January 24, 2022 Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults February 25, 2019 Load more HOT NEWS Improving cancer care for the LGBTQ+ community Foster Teen With A Passion For Painting Is Patiently Waiting For... What Are Patient-Reported Outcomes and Why Are They Important in Cancer... Our sun safety messaging tours the UK with the NIVEA Sun...
